Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Enterprise Value (2022 - 2025)

Historic Enterprise Value for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$325.3 million.

  • Axsome Therapeutics' Enterprise Value rose 62.35% to -$325.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$325.3 million, marking a year-over-year increase of 62.35%. This contributed to the annual value of -$315.4 million for FY2024, which is 1834.32% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Enterprise Value stood at -$325.3 million, which was up 62.35% from -$303.0 million recorded in Q2 2025.
  • Axsome Therapeutics' Enterprise Value's 5-year high stood at -$73.4 million during Q2 2022, with a 5-year trough of -$437.1 million in Q2 2023.
  • Over the past 4 years, Axsome Therapeutics' median Enterprise Value value was -$315.4 million (recorded in 2024), while the average stood at -$286.1 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 49552.18% in 2023, then skyrocketed by 2777.61% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Enterprise Value (Quarter) stood at -$200.8 million in 2022, then tumbled by 92.29% to -$386.2 million in 2023, then grew by 18.34% to -$315.4 million in 2024, then fell by 3.15% to -$325.3 million in 2025.
  • Its Enterprise Value was -$325.3 million in Q3 2025, compared to -$303.0 million in Q2 2025 and -$300.9 million in Q1 2025.